Alport综合征囊性表型的临床意义
该回顾性队列研究纳入108例Alport综合征(AS)患者和79例IgA肾病(IgAN)对照,评估肾脏囊性表型的患病率及临床意义。结果显示AS组囊性表型患病率为38%,显著高于IgAN组的19%(P=0.002),且囊性表型与年龄较大和eGFR下降更快相关。
要点
- AS患者中囊性肾脏表型常见,患病率达38%。
- AS囊性表型患病率显著高于IgAN对照(42% vs 19%,P=0.002)。
- 囊性表型与年龄较大及eGFR下降更快相关。
核心结论
- 囊性肾脏表型在Alport综合征中常见,提示致病基因变异可能参与囊肿形成。
研究设计与样本
- 回顾性队列研究,纳入108例Alport综合征患者和79例IgA肾病对照。
主要发现
- AS组囊性表型患病率为38%,IgAN组为19%,组间差异有统计学意义(P=0.002)。
- AS囊性表型患者年龄更大且eGFR下降更明显。
- 除3例肾脏总体积增大 mimicking 常染色体显性多囊肾病外,其余患者肾脏大小正常。
关键数值与推荐
- 囊性肾脏表型定义为超声检查发现每侧肾脏≥3个囊肿。
- AS组中68%的基因诊断患者为常染色体显性AS。
临床怎么用
- 对Alport综合征患者应关注肾脏囊性表型,其与肾功能下降更快相关。
局限性
- 回顾性、单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Alport syndrome (AS) is the most common genetic glomerular disease caused by mutations that affect type IV collagen. However, the clinical characteristics and significance of AS with kidney cysts are not well defined. This study investigated the prevalence and clinical significance of cystic kidney phenotype in AS. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: One hundred-eight patients with AS and a comparison cohort of 79 patients with IgA nephropathy (IgAN). Clinical, genetic, and imaging data were collected from medical records. EXPOSURE: Cystic kidney phenotype evaluated by ultrasonography and defined as the presence of≥3 cysts in each kidney; demographic characteristics and estimated glomerular filtration rate (eGFR) at disease onset. OUTCOME: Cystic kidney phenotype in the AS and IgAN cohorts; time to chronic kidney disease (CKD) stage 3b and longitudinal changes in eGFR in the AS cohort. ANALYTICAL APPROACH: Logistic regression analysis to test independent strengths of associations of clinical/demographic features with the binary outcome of cystic phenotype. Survival analysis for the outcome of reaching CKD stage 3b and linear mixed models for changes in eGFR over time in the AS cohort. RESULTS: We studied 108 patients with AS; 76 (70%) had a genetic diagnosis. Autosomal dominant AS was prevalent, accounting for 68% of patients with a genetic diagnosis. Cystic kidney phenotype was observed in 38% of patients with AS and was associated with normal-sized kidneys in all but 3 patients, who showed increased total kidney volume, mimicking autosomal dominant polycystic kidney disease. The prevalence of cystic kidney phenotype was significantly higher in patients with AS when compared with the group of patients with IgAN (42% vs 19%; P=0.002). Patients with the cystic kidney phenotype were older and had more marked reduction in eGFR than patients without cystic changes. Among patients with AS, the cystic phenotype was associated with older age and a faster decline eGFR. LIMITATIONS: Retrospective, single-center study. CONCLUSIONS: Cystic kidney phenotype is a common finding in AS. The cystic kidney phenotype is a common finding in AS, suggesting a possible role in cystogenesis for the genetic variants that cause this disease. PLAIN-LANGUAGE SUMMARY: Hematuria is the classic renal presentation of Alport syndrome (AS), a hereditary glomerulopathy caused by pathogenic variants of the COL4A3-5 genes. An atypical kidney cystic phenotype has been rarely reported in individuals with these variants. To determine the prevalence of kidney cysts, we performed abdominal ultrasonography in a large group of patients with AS and a comparison group of patients with another glomerular kidney disease, IgA nephropathy (IgAN). Multiple kidney cysts, usually with normal kidney volume, were found in 38% of patients with AS. A few patients' kidney volumes were large enough to mimic a different hereditary cystic kidney disease, autosomal dominant polycystic kidney disease. The overall prevalence of kidney cysts in AS was more than double that observed in the well-matched comparison group with IgAN. These findings emphasize the high prevalence of cystic kidney phenotype in AS, suggesting a likely association between the genetic variants that cause this disease and the development of kidney cysts.
引用
- Zeni L, Mescia F, Toso D, et al. Clinical Significance of the Cystic Phenotype in Alport Syndrome. Am J Kidney Dis. 2024. PMID: 38514012. doi:10.1053/j.ajkd.2024.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。